Effectual, an AWS Premier Tier Services Partner specializing in enterprise digital transformation, is proud to announce it has been named the winner of the 2025 AWS Public Sector Consulting Partner of ...

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the oral presentation of positive results ...

Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy ...

Cancer is often perceived as a fate, but what if it could be avoided even before it manifests? Scientists have just taken a ...

BGB-16673 showed high overall response rates in relapsed/refractory CLL/SLL, with a notable 94.4% response at the 200-mg dose level. Safety analysis revealed that 95.6% of patients experienced ...

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S.

Bladder carcinoma usually arises from the urothelium and is strongly linked to smoking and chemical exposure. It often ...

Data from Phase 2 Trials Underscore Cardioprotective Potential GRAND RAPIDS, Mich., Dec. 9, 2025 /PRNewswire/ -- Cirius Therapeutics, ...

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...

Opening Bid Unfiltered is available on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. The battle to ...

Genmab (GMAB) announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE CLL-1 trial evaluating the efficacy and safety of ...

China-Pakistan Study Centre (CPSC) at the Institute of Strategic Studies Islamabad (ISSI) organized the fifth working session of the ...